Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN)

CAPS Rating: 3 out of 5

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

Recs

0
Player Avatar acts20 (34.55) Submitted: 1/30/2012 4:43:04 PM : Outperform Start Price: $14.40 AMLN Score: +0.64

just going on buy out rumors,

Featured Broker Partners


Advertisement